Tesamorelin
A synthetic full-length GHRH analogue (44 amino acids) with an N-terminal trans-3-hexenoic acid modification that improves metabolic stability relative to native GHRH; FDA-approved as Egrifta SV for HIV-associated lipodystrophy in adults. Phase 3 RCT data support visceral fat reduction in the approved indication; evidence for the off-label applications most frequently discussed in community settings — body composition in otherwise healthy adults — is substantially weaker. Available only by prescription.
Side effects & risks
Tesamorelin has a well-characterised human adverse-event profile because it was evaluated in two Phase III randomised, double-blind, placebo-controlled trials prior to FDA approval, and post-marketing pharmacovigilance data from the approved Egrifta SV product exists. The approved indication (HIV-associated lipodystrophy) involves a specific patient population, and adverse-event findings apply to that population. Research-chemical tesamorelin sold outside the pharmaceutical approval framework is not equivalent to Egrifta SV.
In the Phase III trials — Falutz et al. (2007, New England Journal of Medicine, vol. 357; PMID 18057338) and the confirmatory trial (Falutz et al., 2010, Journal of Acquired Immune Deficiency Syndromes, vol. 53; PMID 20101189) — common adverse events in the tesamorelin arms included injection-site reactions (erythema, pruritus, pain; occurring in approximately 25–40% of participants), peripheral oedema (approximately 6% vs 2% placebo), myalgia, and arthralgia. Transient glucose elevations were documented; the prescribing information notes the need for glucose monitoring in patients with pre-existing diabetes or at risk.
IGF-1 elevation is a pharmacodynamic consequence of tesamorelin administration (via GH stimulation). The relationship between elevated IGF-1 and cancer risk in epidemiological contexts is noted (Pollak et al., 2004, Nature Reviews Cancer, vol. 4; PMID 15229476). The prescribing information for Egrifta SV includes a warning that tesamorelin should not be initiated in patients with active malignancy and should be discontinued if malignancy is diagnosed during treatment. This is a significant clinical risk flag that community users considering tesamorelin for off-label purposes must understand.
Water retention and oedema, reflecting GH-mediated effects on renal sodium handling, were observed in trials. Carpal tunnel syndrome-like symptoms (paraesthesia, tingling in extremities) were reported in some participants — a class effect of GH elevation.
Tesamorelin is an FDA-approved drug (Egrifta SV) for the specific indication of HIV-associated lipodystrophy. Its use in this indication is supported by Phase III trial data. Off-label use, including any use for body composition in individuals without HIV-associated lipodystrophy, is not covered by the approval and has not been evaluated in dedicated controlled trials in those populations. Research-chemical tesamorelin is not manufactured to pharmaceutical standards; dose accuracy, purity, and sterility are not regulated.
Evidence summary
Latest studies
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
In a pilot study, 22 adults whose thinking skills ranged from normal to mildly impaired were randomly assigned to either a low dose (1 mg) of tesamorelin — a lab-made version of a hormone that prompts the body to release growth hormone — or a placebo, given for 10 weeks. Neither group showed clear, statistically meaningful changes in memory and thinking tests, body composition, fatigue, sleep, or brain scans when analyzed the usual way. When the researchers applied advanced pattern-finding software, they spotted possible treatment-related differences in a few brain areas tied to thinking. The authors stress this was a small, early study designed mainly to test whether the combined approach of cognitive tests plus brain imaging and machine learning could pick up subtle effects. Its findings are preliminary and would need larger trials to confirm.
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
This article describes the plan for an upcoming clinical trial called TRIUMPH — it is a study protocol, not results. The trial will test whether tesamorelin, an injectable drug that stimulates the body's own growth-hormone system, can improve physical function when combined with exercise in older adults living with HIV. Researchers will enroll 100 sedentary adults aged 50 to 80 who are frail or at risk of frailty and carry excess belly fat. Participants will be randomly assigned to receive either tesamorelin or a placebo alongside a home-based, partly supervised exercise program for 24 weeks, followed by another 24 weeks of exercising on their own. Neither participants nor researchers will know who gets the real drug (a double-blind design). The team will measure physical function, muscle amount and quality, quality of life, exercise participation, and muscle energy production at 24 and 48 weeks. Because this only lays out how the study will be run, there are no results yet — the findings will come later and could guide future ways to help older adults with HIV stay physically capable.
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
Doctors describe two adults with well-controlled HIV who both had extra fat around the abdomen but very different body types. The first, who was not obese, had a larger waistline and abnormal cholesterol; treatment with tesamorelin (a drug that selectively shrinks deep belly fat) was associated with a smaller waist, better lipids, and improved wellbeing. The second, who was obese, took a GLP-1 weight-loss medication only intermittently and kept fluctuating weight and stubborn belly fat; adding tesamorelin gave a more targeted reduction in deep abdominal fat. The authors use these two stories to argue that deep belly fat can exist regardless of overall weight and may need treatment aimed specifically at it rather than at general weight loss. Because this is just two patients with no comparison group, it illustrates a point rather than proving one approach works better than another.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Anyone use Tesa before reaching their goal weight?”
A thread asking whether others have started tesamorelin before reaching their goal weight, seeking community experiences on sequencing it within a body-composition protocol.
“"CJC-1295 + Ipa no DAC" VS "Tesamorelin + Ipa"”
A comparison thread weighing CJC-1295 (no DAC) plus Ipamorelin against Tesamorelin plus Ipamorelin, asking which GHRH-analog pairing the community regards as more effective for their goals.
“CJC-1295 + Ipamorelin / Tesamorelin vs GH – insulin sensitivity concerns with good baseline labs”
A user compares growth hormone secretagogue options (CJC-1295 plus ipamorelin, or tesamorelin) against exogenous GH, focusing on possible insulin-sensitivity impact for someone whose baseline metabolic labs are currently good.
“BPC-157, TB500, Tesa, growth hormone peptides and affects on people in remission from cancer”
A poster asks how BPC-157, TB-500, tesamorelin, and other growth-hormone-axis peptides might affect people in remission from cancer, opening a safety-focused discussion about whether growth-promoting compounds carry theoretical risks in that population.
“RETA + TESA 10 WEEKS”
A user shares a 10-week update on a combined retatrutide and tesamorelin protocol, a stack the community discusses for body-composition goals, inviting discussion of results and dosing over the cycle.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| HIV-associated lipodystrophy (FDA-approved protocol) | SC injection (abdomen) | 2 mg | Once daily | Ongoing with IGF-1 monitoring; as per prescribing information |
| Off-label fat reduction (community-reported) | SC injection | 1–2 mg | Once daily or 5 days on / 2 days off | Not established; community reports vary |
Frequently asked questions
- Is tesamorelin an FDA-approved drug?
- Yes. Tesamorelin is approved by the FDA as Egrifta SV (Theratechnologies) for the reduction of excess visceral fat in adults with HIV-associated lipodystrophy. The approval is based on two Phase III randomised controlled trials in this specific patient population. The Egrifta SV formulation received FDA approval in 2019 as a formulation change; the underlying indication did not change. A further extended-release formulation (Egrifta WR) received FDA approval in March 2025. Off-label use of tesamorelin — including use for body composition in individuals without HIV-associated lipodystrophy — is not covered by this approval.
- What are the known risks of tesamorelin?
- In Phase III trials (Falutz et al., 2007, PMID 18057338; Falutz et al., 2010, PMID 20101189), common adverse events included injection-site reactions (in approximately 25–40% of participants), peripheral oedema (around 6%), myalgia, and arthralgia. Glucose elevations were documented; monitoring is required for patients with diabetes. A key risk is IGF-1 elevation: the Egrifta SV prescribing information includes a warning against use in patients with active malignancy, due to the epidemiological association between elevated IGF-1 and cancer risk (Pollak et al., 2004, PMID 15229476). Carpal tunnel syndrome-like symptoms are a class effect of GH elevation.
- How is tesamorelin different from sermorelin?
- Both are synthetic GHRH analogues that stimulate pituitary GH release via the same GHRH receptor. The key differences are: (1) tesamorelin is the full 44-amino-acid GHRH sequence, while sermorelin is the first 29 amino acids; (2) tesamorelin carries an N-terminal trans-3-hexenoic acid modification that improves metabolic stability by resisting DPP-IV degradation; (3) tesamorelin has FDA approval for HIV-associated lipodystrophy supported by Phase III trials, while sermorelin's FDA approval (Geref) was for paediatric GH deficiency and was voluntarily withdrawn commercially in 2008.
- Can tesamorelin be used for fat loss without HIV?
- The FDA approval covers only HIV-associated lipodystrophy. Post-approval research has explored the visceral fat reduction mechanism in other populations, but this work is limited and does not constitute adequate controlled trial evidence establishing benefit in individuals without HIV-associated lipodystrophy. Research-chemical tesamorelin used outside an approved indication is not subject to the safety monitoring embedded in the approved prescribing framework.
- Is tesamorelin legal to buy or use?
- Egrifta SV (the FDA-approved tesamorelin pharmaceutical) is a prescription-only drug in the United States. Research-chemical versions of tesamorelin sold outside this framework are not subject to pharmaceutical manufacturing controls. Their regulatory status varies by country; in many jurisdictions they require a prescription or may be subject to import restrictions. Verify current status with a qualified legal or clinical professional.